samedan logo
 
 
spacer
home > pmps > winter 2020 > transdermal delivery systems
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Transdermal Delivery Systems




Transdermal delivery systems (TDS) are complex combination products typically composed of multilayer polymer components designed to deliver drugs systemically. As a result of their complex design and unique dosing requirements, designing and executing extractable and leachable (E&L) studies can be a unique challenge. One of the biggest hurdles has been the overall lack of direct regulatory guidance in the development of study designs requiring the sponsors of drug products to make regulatory justifications. Until recently, the main regulatory guidance for E&L for container/closure systems was the 1999 guidance, which included the table that correlates the likelihood that leachables would occur and the risk associated with the route of administration – which clearly ranks transdermal delivery systems as a high risk for both the potential for leachables and the route of administration (1).

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
About the author


Dr Wayland Rushing has 20 years of chemical, manufacturing, and controls (CMC) analytical testing experience, including over 15 years of experience in E&L programmes. As the Director of Scientific Affairs, he is responsible for designing and implementing CMC testing programmes for Eurofins clients, including E&L programmes for pressurised metered dose inhalers, dry powder inhalers, nebulisers, and prefilled syringes, along with a variety of other drug delivery and container/closure systems. He earned his Bachelor’s degree from Westminster College, US, and his PhD in Chemistry from the University of Missouri, US.
Print this page
Send to a friend
Privacy statement
News and Press Releases

Nemera to build state-of-the-art manufacturing facility in Poland to serve more customers and patients

Based in Szczecin, this facility extends Nemera’s manufacturing capabilities and will bring more drug delivery device solutions to patients. Following the dynamic growth of the drug delivery devices market, as a world leader, Nemera is thrilled to extend its manufacturing capabilities in Poland.
More info >>

White Papers

Utilising Big Data to Produce Faster and Cheaper Clinical Research

Medical Research Network (MRN) Limited

Recruitment and retention of patients remains the major challenge to ensuring trials run as fast as possible and give them the statistical power they are designed to produce. This is not just about getting better any more - but about stopping the deterioration of these metrics in modern clinical trials.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement